atomoxetine hydrochloride has been researched along with Nerve Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harkin, A; McNamara, C; O'Neill, E; Yssel, JD | 1 |
| Bally-Cuif, L; Chaminade, M; Coolen, M; Lange, M; Lesch, KP; Merker, S; Norton, W; Proft, F; Schmitt, A; Vernier, P | 1 |
2 other study(ies) available for atomoxetine hydrochloride and Nerve Degeneration
| Article | Year |
|---|---|
Pharmacological targeting of β
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Inflammatory Agents; Atomoxetine Hydrochloride; Brain; Clenbuterol; Disease Models, Animal; Formoterol Fumarate; Lipopolysaccharides; Male; Microglia; Motor Activity; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Receptors, Adrenergic, beta-2 | 2020 |
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diencephalon; Disease Models, Animal; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Gene Knockdown Techniques; Methylphenidate; Molecular Imaging; Motor Activity; Nerve Degeneration; Propylamines; Receptors, Peptide; Zebrafish | 2012 |